Brian Bartilol Awarded International PhD Scholarship at Wageningen University & Research
Congratulations to Brian Bartilol on being awarded the Wageningen Graduate
The Beyond Survival Study team holds stakeholder feedback meetings at study sites
The Beyond Survival Study team conducted stakeholder feedback meetings at
NEWRISK project commences implementation study in Kisumu county
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
Dr. Helen Nabwera appointed as Head of clinical Research, KEMRI Wellcome Trust Research Programme
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
VIGOR project convenes national stakeholder meeting
The Virus Genomics for Outbreak Response (ViGOR) project team in
Professor Ambrose Agweyu Appointed as Deputy Director, Nairobi of the KEMRI-Wellcome Research Programme
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
Professor Isabella Oyier Appointed as Deputy Director, Kilifi of the KEMRI-Wellcome Research Programme
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
From Kilifi to the World: Rethinking Malaria Control Through Three Decades of Research
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
Championing Ethical Research: Dorcas Kamuya on Community, Science, and Women in Leadership
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
Advancing Epilepsy Care in Africa: Insights from the EPInA Dissemination Meeting in Nairobi
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
AMR Kenya 2026 Conference: Working Together to Tackle Antimicrobial Resistance
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.
Novo Nordisk Foundation Pays Courtesy Visit to the Programme
Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.